Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)

Published:2019-03-25 Issue:7 Volume:22 Page:625-637
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Ondhia Umang¹^ORCID,Conter H. J.²³,Owen Scott⁴,Zhou Anna⁵,Nam Julian¹,Singh Sumeet⁵,Abdulla Ahmed⁶,Chu Paula⁶,Felizzi Federico⁶,Paracha Noman⁶,Sangha Randeep⁷

Affiliation:

1. Hoffmann-La Roche Limited, Global Access, Mississauga, Canada;

2. Division of Oncology, William Osler Health System, Toronto, Canada;

3. Division of Medical Oncology, Western University, London, Canada;

4. Department of Oncology, McGill University, Montreal, Canada;

5. Cornerstone Research Group, Burlington, Canada;

6. F. Hoffmann-La Roche Limited, Basel, Switzerland;

7. Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1590842

Reference64 articles.

1. Canadian Cancer Society. Canadian Cancer Statistics 2016. 2016 [Accessed: 2017 Dec]. Available online at: http://www.cancer.ca/∼/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la=en.

2. Non–Small Cell Lung Cancer

3. Canadian Cancer Society. Canadian Cancer Statistics 2017. 2017 [Accessed: 2017 Jul]. Available online at: http://www.cancer.ca/∼/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2017-EN.pdf?la=en.

4. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

5. Extending Survival of Stage IV Non-Small Cell Lung Cancer

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States;Frontiers in Pharmacology;2024-02-05

2. Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis;Journal of Thoracic Disease;2024-02

3. Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective;PharmacoEconomics;2023-11-20

4. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors;International Journal of Molecular Sciences;2023-03-15

5. Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment;PharmacoEconomics;2023-01-19